Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AICH-PXZY is a Traditional Chinese Medicine (TCM) formulation, specifically a "Removing Blood Stasis Decoction," developed by the Guangzhou University of Chinese Medicine. It is intended for the treatment of acute cerebral hemorrhage (ICH) and associated complications such as stroke-associated pneumonia. The therapy follows the TCM principle of "Removing Blood Stasis" (Po Xue Zhu Yu) to facilitate the resolution of intracranial hematomas and mitigate secondary brain injury. Clinical research, including a Phase 4 trial (NCT04104399), focuses on its safety, clinical efficacy, and its potential to modulate the intestinal microbial flora through the gut-brain axis in patients treated within 6 to 72 hours of symptom onset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Removing Blood Stasis Decoction.